richardwilliam93  created a new article
1 y ·Translate

Regulatory spotlight: Novartis’s remibrutinib likely to progress after positive urticaria trial | #urticaria Pipeline Drugs Market

Regulatory spotlight: Novartis’s remibrutinib likely to progress after positive urticaria trial

Regulatory spotlight: Novartis’s remibrutinib likely to progress after positive urticaria trial

Urticaria is defined as a skin lesion consisting of a wheal-and-flare reaction in which localized intracutaneous edema is surrounded by an area of redness that is typically pruritic. Individual hives can last as briefly as 30 minutes to as long as 36 hours.